Published in EMBO Mol Med on August 01, 2009
Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). Blood (2011) 2.96
Retracted MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem (2010) 2.34
Up-regulation of microRNA-155 in macrophages contributes to increased tumor necrosis factor {alpha} (TNF{alpha}) production via increased mRNA half-life in alcoholic liver disease. J Biol Chem (2010) 2.16
Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer. Proc Natl Acad Sci U S A (2011) 1.96
Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proc Natl Acad Sci U S A (2012) 1.91
Virally induced cellular microRNA miR-155 plays a key role in B-cell immortalization by Epstein-Barr virus. J Virol (2010) 1.83
miR-221 and miR-155 regulate human dendritic cell development, apoptosis, and IL-12 production through targeting of p27kip1, KPC1, and SOCS-1. Blood (2011) 1.73
Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene (2013) 1.71
IL-10 inhibits miR-155 induction by toll-like receptors. J Biol Chem (2010) 1.65
Molecular mechanisms that influence the macrophage m1-m2 polarization balance. Front Immunol (2014) 1.62
Efficient inhibition of miR-155 function in vivo by peptide nucleic acids. Nucleic Acids Res (2010) 1.41
Cell-free Circulating miRNA Biomarkers in Cancer. J Cancer (2012) 1.37
Elevated miR-155 promotes inflammation in cystic fibrosis by driving hyperexpression of interleukin-8. J Biol Chem (2011) 1.30
MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood (2014) 1.19
MiR-155 promotes proliferation of human breast cancer MCF-7 cells through targeting tumor protein 53-induced nuclear protein 1. J Biomed Sci (2013) 1.18
The multiple roles of microRNA-155 in oncogenesis. J Clin Bioinforma (2013) 1.18
Akt and mTOR in B Cell Activation and Differentiation. Front Immunol (2012) 1.16
microRNA-155 silencing inhibits proliferation and migration and induces apoptosis by upregulating BACH1 in renal cancer cells. Mol Med Rep (2012) 1.15
MicroRNA-214 suppresses growth, migration and invasion through a novel target, high mobility group AT-hook 1, in human cervical and colorectal cancer cells. Br J Cancer (2016) 1.14
Murine pancreatic adenocarcinoma dampens SHIP-1 expression and alters MDSC homeostasis and function. PLoS One (2011) 1.13
Regulation of breast cancer and bone metastasis by microRNAs. Dis Markers (2013) 1.12
BCL6 positively regulates AID and germinal center gene expression via repression of miR-155. J Exp Med (2012) 1.11
Coordinate suppression of B cell lymphoma by PTEN and SHIP phosphatases. J Exp Med (2010) 1.10
Upregulation of MiR-155 in nasopharyngeal carcinoma is partly driven by LMP1 and LMP2A and downregulates a negative prognostic marker JMJD1A. PLoS One (2011) 1.09
A role for microRNA-155 modulation in the anti-HIV-1 effects of Toll-like receptor 3 stimulation in macrophages. PLoS Pathog (2012) 1.05
Regulation of cancer metastasis by cell-free miRNAs. Biochim Biophys Acta (2014) 1.02
Oncogenic IRFs provide a survival advantage for Epstein-Barr virus- or human T-cell leukemia virus type 1-transformed cells through induction of BIC expression. J Virol (2011) 1.00
The duality of oncomiR addiction in the maintenance and treatment of cancer. Cancer J (2012) 0.99
Pathogenic mechanisms of deregulated microRNA expression in thyroid carcinomas of follicular origin. Thyroid Res (2011) 0.99
Deletion of microRNA-155 reduces autoantibody responses and alleviates lupus-like disease in the Fas(lpr) mouse. Proc Natl Acad Sci U S A (2013) 0.97
miR-155 regulates HGAL expression and increases lymphoma cell motility. Blood (2011) 0.96
Differential micro-RNA expression in primary CNS and nodal diffuse large B-cell lymphomas. Neuro Oncol (2011) 0.96
MyD88-dependent SHIP1 regulates proinflammatory signaling pathways in dendritic cells after monophosphoryl lipid A stimulation of TLR4. J Immunol (2011) 0.96
Regulation of B-cell development and function by microRNAs. Immunol Rev (2013) 0.95
The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions. Front Immunol (2012) 0.95
Abnormal microRNA expression in Ts65Dn hippocampus and whole blood: contributions to Down syndrome phenotypes. Dev Neurosci (2011) 0.92
Discovery and development of small molecule SHIP phosphatase modulators. Med Res Rev (2013) 0.91
Physiological roles of miR-155. Immunology (2015) 0.89
MicroRNA-155 promotes bladder cancer growth by repressing the tumor suppressor DMTF1. Oncotarget (2015) 0.87
Diffuse large B-cell lymphoma with combined TP53 mutation and MIR34A methylation: Another "double hit" lymphoma with very poor outcome? Oncotarget (2014) 0.87
MicroRNA control of myelopoiesis and the differentiation block in acute myeloid leukaemia. J Cell Mol Med (2012) 0.86
Human mesenchymal stem cells suppress the stretch-induced inflammatory miR-155 and cytokines in bronchial epithelial cells. PLoS One (2013) 0.83
MicroRNAs, Major Players in B Cells Homeostasis and Function. Front Immunol (2014) 0.83
Quaking and miR-155 interactions in inflammation and leukemogenesis. Oncotarget (2015) 0.83
MicroRNAs: New players in cancer prevention targeting Nrf2, oxidative stress and inflammatory pathways. Curr Pharmacol Rep (2015) 0.82
Down-regulation of microRNA-155 attenuates retinal neovascularization via the PI3K/Akt pathway. Mol Vis (2015) 0.81
Clinical significance of miR-155 expression in breast cancer and effects of miR-155 ASO on cell viability and apoptosis. Oncol Rep (2012) 0.81
Role of microRNAs on therapy resistance in Non-Hodgkin's lymphoma. Int J Clin Exp Med (2014) 0.81
Inhibition of MiR-155 suppresses cell migration in nasopharyngeal carcinoma through targeting ZDHHC2. Int J Clin Exp Med (2015) 0.81
Transfection of microRNA Mimics Should Be Used with Caution. Front Genet (2015) 0.80
Role of microRNA deregulation in the pathogenesis of diffuse large B-cell lymphoma (DLBCL). Leuk Res (2013) 0.80
miR-155 downregulates ErbB2 and suppresses ErbB2-induced malignant transformation of breast epithelial cells. Oncogene (2016) 0.79
MicroRNAs in Lymphoma: Regulatory Role and Biomarker Potential. Curr Genomics (2015) 0.78
Therapeutic strategy with artificially-designed i-lncRNA targeting multiple oncogenic microRNAs exhibits effective antitumor activity in diffuse large B-cell lymphoma. Oncotarget (2016) 0.77
MicroRNA-related polymorphisms and non-Hodgkin lymphoma susceptibility in the Multicenter AIDS Cohort Study. Cancer Epidemiol (2016) 0.76
MicroRNA-155 promotes the pathogenesis of experimental colitis by repressing SHIP-1 expression. World J Gastroenterol (2017) 0.75
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 64.32
Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer (2006) 46.47
MicroRNA signatures in human cancers. Nat Rev Cancer (2006) 46.29
A microRNA polycistron as a potential human oncogene. Nature (2005) 40.21
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2002) 32.26
RAS is regulated by the let-7 microRNA family. Cell (2005) 30.24
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med (2002) 24.07
miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A (2005) 21.51
MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A (2004) 14.59
Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med (2002) 14.01
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood (2003) 13.92
Regulation of the germinal center response by microRNA-155. Science (2007) 12.25
MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci U S A (2007) 11.42
Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A (2006) 10.65
Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol (2007) 8.05
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol (2006) 7.14
MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol (2006) 5.40
MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. Int J Cancer (2007) 2.94
Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas. Blood (2008) 2.36
Mature follicular dendritic cell networks depend on expression of lymphotoxin beta receptor by radioresistant stromal cells and of lymphotoxin beta and tumor necrosis factor by B cells. J Exp Med (1999) 2.11
Diffuse large cell lymphoma. Curr Opin Oncol (2001) 2.10
Coordinated expression of microRNA-155 and predicted target genes in diffuse large B-cell lymphoma. Cancer Genet Cytogenet (2008) 2.01
Phosphoinositide 3-kinase and its targets in B-cell and T-cell signaling. Curr Opin Immunol (2004) 1.47
Serum levels of inflammatory cytokines at diagnosis correlate to the bcl-6 and CD10 defined germinal centre (GC) phenotype and bcl-2 expression in patients with diffuse large B-cell lymphoma. Br J Haematol (2005) 0.91
WHO-EORTC classification for cutaneous lymphomas. Blood (2005) 12.14
Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature (2007) 7.04
Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell (2005) 4.30
Immunomodulatory functions of type I interferons. Nat Rev Immunol (2012) 3.73
Identification of a nuclear Stat1 protein tyrosine phosphatase. Mol Cell Biol (2002) 3.57
Activation of IKKalpha target genes depends on recognition of specific kappaB binding sites by RelB:p52 dimers. EMBO J (2004) 3.32
Hypoxia-inducible factor 1alpha is essential for cell cycle arrest during hypoxia. Mol Cell Biol (2003) 3.10
Codon-usage-based inhibition of HIV protein synthesis by human schlafen 11. Nature (2012) 2.98
Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). Blood (2011) 2.96
Distinct functions for the transcription factor Foxo1 at various stages of B cell differentiation. Nat Immunol (2008) 2.50
Alternative and classical NF-kappa B signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease. Immunity (2006) 2.33
Arginine methylation of NIP45 modulates cytokine gene expression in effector T lymphocytes. Mol Cell (2004) 2.20
Vav1/2/3-null mice define an essential role for Vav family proteins in lymphocyte development and activation but a differential requirement in MAPK signaling in T and B cells. J Exp Med (2003) 2.15
Prevalence and characterization of uremic pruritus in patients undergoing hemodialysis: uremic pruritus is still a major problem for patients with end-stage renal disease. J Am Acad Dermatol (2003) 2.15
Pten inactivation alters peripheral B lymphocyte fate and reconstitutes CD19 function. Nat Immunol (2003) 2.05
Epigenetic changes in cancer. APMIS (2007) 1.96
Regulation of class-switch recombination and plasma cell differentiation by phosphatidylinositol 3-kinase signaling. Immunity (2006) 1.94
IKK beta is required for peripheral B cell survival and proliferation. J Immunol (2003) 1.92
Protein tyrosine phosphatases in autoimmunity. Annu Rev Immunol (2008) 1.90
Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol (2012) 1.87
Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. Immunol Rev (2011) 1.70
Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3/Stat3 signaling pathway. J Invest Dermatol (2011) 1.70
MicroRNAs and cancer. APMIS (2007) 1.66
Act1, a negative regulator in CD40- and BAFF-mediated B cell survival. Immunity (2004) 1.65
Critical role for Stat3 in T-dependent terminal differentiation of IgG B cells. Blood (2005) 1.60
Impaired development of CD4+ CD25+ regulatory T cells in the absence of STAT1: increased susceptibility to autoimmune disease. J Exp Med (2003) 1.59
Cutting edge: role of STAT1, STAT3, and STAT5 in IFN-alpha beta responses in T lymphocytes. J Immunol (2005) 1.57
Cryopreserved ovarian cortex from patients with leukemia in complete remission contains no apparent viable malignant cells. Blood (2012) 1.57
Kinase MEKK1 is required for CD40-dependent activation of the kinases Jnk and p38, germinal center formation, B cell proliferation and antibody production. Nat Immunol (2006) 1.52
WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects. J Cutan Pathol (2005) 1.51
The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol (2006) 1.50
Selective IgE deficiency, immune dysregulation, and autoimmunity. Allergy Asthma Proc (2014) 1.49
Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol (2012) 1.48
miR-449 inhibits cell proliferation and is down-regulated in gastric cancer. Mol Cancer (2011) 1.46
Genetic and epigenetic alterations of the reduced folate carrier in untreated diffuse large B-cell lymphoma. Eur J Haematol (2007) 1.46
The Dead Sea, a unique natural health resort. Isr Med Assoc J (2006) 1.45
Infectious mononucleosis, childhood social environment, and risk of Hodgkin lymphoma. Cancer Res (2007) 1.45
Are patients with psoriasis susceptible to the classic risk factors for actinic keratoses? Arch Dermatol (2004) 1.44
Treatment of lymphangioma circumscriptum with combined radiofrequency current and 900 nm diode laser. Dermatol Surg (2006) 1.41
Genome-wide profiling identifies a DNA methylation signature that associates with TET2 mutations in diffuse large B-cell lymphoma. Haematologica (2013) 1.40
LYP inhibits T-cell activation when dissociated from CSK. Nat Chem Biol (2012) 1.37
STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma. Cell Cycle (2013) 1.33
MicroRNAs in the immune response. Cytokine (2008) 1.31
Vav1 controls DAP10-mediated natural cytotoxicity by regulating actin and microtubule dynamics. J Immunol (2006) 1.30
Protein tyrosine phosphatase PTPN22 in human autoimmunity. Autoimmunity (2007) 1.28
Cutting edge: anthrax lethal toxin inhibits activation of IFN-regulatory factor 3 by lipopolysaccharide. J Immunol (2004) 1.28
The physiologic role of CD19 cytoplasmic tyrosines. Immunity (2002) 1.25
Expression profile of host restriction factors in HIV-1 elite controllers. Retrovirology (2013) 1.24
Cyclin D3 is selectively required for proliferative expansion of germinal center B cells. Mol Cell Biol (2010) 1.24
Suppression of phosphatidylinositol 3,4,5-trisphosphate production is a key determinant of B cell anergy. Immunity (2009) 1.23
A lymphotoxin-IFN-beta axis essential for lymphocyte survival revealed during cytomegalovirus infection. J Immunol (2005) 1.20
CD19 function in early and late B cell development: I. Maintenance of follicular and marginal zone B cells requires CD19-dependent survival signals. J Immunol (2003) 1.20
Lipocalin 2 is protective against E. coli pneumonia. Respir Res (2010) 1.19
Arginine methylation of RNA helicase a determines its subcellular localization. J Biol Chem (2004) 1.19
CD19 function in early and late B cell development. II. CD19 facilitates the pro-B/pre-B transition. J Immunol (2003) 1.18
Allelic methylation levels of the noncoding VTRNA2-1 located on chromosome 5q31.1 predict outcome in AML. Blood (2011) 1.17
Ectopic expression of B-lymphoid kinase in cutaneous T-cell lymphoma. Blood (2009) 1.15
Cutting edge: apoptosis-regulating signal kinase 1 is required for reactive oxygen species-mediated activation of IFN regulatory factor 3 by lipopolysaccharide. J Immunol (2006) 1.15
Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas. Histopathology (2009) 1.14
Vav1 promotes T cell cycle progression by linking TCR/CD28 costimulation to FOXO1 and p27kip1 expression. J Immunol (2006) 1.12
Coordinate suppression of B cell lymphoma by PTEN and SHIP phosphatases. J Exp Med (2010) 1.10
CD19 function in central and peripheral B-cell development. Immunol Res (2005) 1.10
Arginine methylation of STAT1 regulates its dephosphorylation by T cell protein tyrosine phosphatase. J Biol Chem (2002) 1.10
Requirement for Rictor in homeostasis and function of mature B lymphoid cells. Blood (2013) 1.09
Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant. Eur J Haematol (2003) 1.09
Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network. J Hematop (2009) 1.07
Equitoxic doses of 5-azacytidine and 5-aza-2'deoxycytidine induce diverse immediate and overlapping heritable changes in the transcriptome. PLoS One (2010) 1.07
Downregulation of miR-125b in metastatic cutaneous malignant melanoma. Melanoma Res (2010) 1.07
Cutting edge: selective tyrosine dephosphorylation of interferon-activated nuclear STAT5 by the VHR phosphatase. J Immunol (2007) 1.05
DLGH1 is a negative regulator of T-lymphocyte proliferation. Mol Cell Biol (2007) 1.04
Apoptotic mechanism in pemphigus autoimmunoglobulins-induced acantholysis--possible involvement of the EGF receptor. Autoimmunity (2006) 1.04
Trends in dermatology publications over the past 15 years. Am J Clin Dermatol (2010) 1.04
Phospholipase Cγ-2 and intracellular calcium are required for lipopolysaccharide-induced Toll-like receptor 4 (TLR4) endocytosis and interferon regulatory factor 3 (IRF3) activation. J Biol Chem (2011) 1.04
Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor. J Clin Pharmacol (2007) 1.02
The Epstein-Barr virus SM protein induces STAT1 and interferon-stimulated gene expression. J Virol (2003) 1.02
Regulation of late B cell differentiation by intrinsic IKKalpha-dependent signals. Proc Natl Acad Sci U S A (2007) 1.02
Increasing incidence of ophthalmic lymphoma in Denmark from 1980 to 2005. Invest Ophthalmol Vis Sci (2008) 1.00
CD98hc facilitates B cell proliferation and adaptive humoral immunity. Nat Immunol (2009) 1.00
Cutting edge: inherent and acquired resistance to radiation-induced apoptosis in B cells: a pivotal role for STAT3. J Immunol (2006) 1.00
MicroRNA-130a-mediated down-regulation of Smad4 contributes to reduced sensitivity to TGF-β1 stimulation in granulocytic precursors. Blood (2011) 0.99
A novel xenograft model of cutaneous T-cell lymphoma. Exp Dermatol (2010) 0.99
Context-specific BAFF-R signaling by the NF-κB and PI3K pathways. Cell Rep (2013) 0.99
Notch1 as a potential therapeutic target in cutaneous T-cell lymphoma. Blood (2010) 0.98
SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study. Br J Haematol (2014) 0.98
A critical role for complement C3d and the B cell coreceptor (CD19/CD21) complex in the initiation of inflammatory arthritis. J Immunol (2005) 0.98
ATM mutations are associated with inactivation of the ARF-TP53 tumor suppressor pathway in diffuse large B-cell lymphoma. Blood (2002) 0.97
Tyk2 and Stat3 regulate brown adipose tissue differentiation and obesity. Cell Metab (2012) 0.97
Microarray-based classification of diffuse large B-cell lymphoma. Eur J Haematol (2005) 0.97
HLA-B35-restricted immune responses against survivin in cancer patients. Int J Cancer (2004) 0.94
Multidentate small-molecule inhibitors of vaccinia H1-related (VHR) phosphatase decrease proliferation of cervix cancer cells. J Med Chem (2009) 0.94
Inhibition of lymphoid tyrosine phosphatase by benzofuran salicylic acids. J Med Chem (2010) 0.94
Arsenic inhibition of the JAK-STAT pathway. Oncogene (2004) 0.94
Investigation of MGMT and DAPK1 methylation patterns in diffuse large B-cell lymphoma using allelic MSP-pyrosequencing. Sci Rep (2013) 0.94